作者
Chloé Prunier, Véronique Josserand, Julien Vollaire, Evelyne Beerling, Christos Petropoulos, Olivier Destaing, Christopher Montemagno, Amandine Hurbin, Renaud Prudent, Leanne De Koning, Reuben Kapur, Pascale A Cohen, Corinne Albiges-Rizo, Jean-Luc Coll, Jacco Van Rheenen, Marc Billaud, Laurence Lafanechere
发表日期
2016/6/15
期刊
Cancer Research
卷号
76
期号
12
页码范围
3541-3552
出版商
American Association for Cancer Research
简介
LIM kinases (LIMK) are emerging targets for cancer therapy, and they function as network hubs to coordinate actin and microtubule dynamics. When LIMKs are inhibited, actin microfilaments are disorganized and microtubules are stabilized. Owing to their stabilizing effect on microtubules, LIMK inhibitors may provide a therapeutic strategy to treat taxane-resistant cancers. In this study, we investigated the effect of LIMK inhibition on breast tumor development and on paclitaxel-resistant tumors, using a novel selective LIMK inhibitor termed Pyr1. Treatment of breast cancer cells, including paclitaxel-resistant cells, blocked their invasion and proliferation in vitro and their growth in vivo in tumor xenograft assays. The tumor-invasive properties of Pyr1 were investigated in vivo by intravital microscopy of tumor xenografts. A striking change of cell morphology was observed with a rounded phenotype arising in a …
引用总数
201620172018201920202021202220232024157374221
学术搜索中的文章